Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Entecavir + sodium bicarbonate is a combination of two agents. Entecavir is a potent, selective guanine nucleoside analogue antiviral drug that inhibits hepatitis B virus (HBV) replication by blocking the activity of viral reverse transcriptase, thereby preventing viral DNA synthesis[2][3][6]. It is primarily used for the treatment of chronic hepatitis B infection in adults and children over two years old with active viral replication and abnormal liver function. Sodium bicarbonate is an alkalinizing agent commonly used to neutralize gastric acid or correct metabolic acidosis; it may also be co-administered to protect drugs from stomach acid degradation or to manage side effects such as acidosis[5]. The combination may be considered when both antiviral therapy and pH regulation are needed, but there are no widely recognized fixed-dose products combining these two ingredients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on entecavir + sodium bicarbonate.